Nilemdo and Nustendi Win Funding In England For High Cholesterol
NICE Is Also Developing Guidance For Novartis’s Cholesterol-Lowering Leqvio
Executive Summary
Around 70,000 adults in England with primary hypercholesterolemia or mixed dyslipidemia will have access to the bempedoic acid ACL inhibitors from Esperion/Daiichi Sankyo.
You may also be interested in...
Novartis Inks World-First Pact With NHS England For Inclisiran
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.